NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2023
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $175,000 — The emergence of the Wuhan new coronavirus (nCoV) initiated efforts to rapidly develop effective medical countermeasures including vaccines and therapeutics against this severe disease. However, there is limited knowledge on polyclonal antibody responses generated following vaccination or nCoV infec…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
JUN WANG · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $211,875 — Project Summary The rapid spread of SARS-CoV-2 and the resulting Coronavirus Disease 2019 (COVID-19) pose a global pandemic. SARS-CoV-2 and its family members share some puzzling, unique pathological features, most notably acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Zhuo Li · CYANVAC, LLC · 2022 · $150,000 — Developing a liquid formulation for CVXGA1 COVID-19 intranasal vaccine ABSTRACT In this Phase I SBIR application, we propose to develop a liquid formulation for CVXGA1 COVID-19 intranasal vaccine. The ongoing global coronavirus disease 2019 (COVID-19) pandemic has resulted in the loss of many lives …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Dan H. Barouch · FRED HUTCHINSON CANCER CENTER · 2022 · $5,663,427 — NOSI: NOT-AI-20-034 FOA: PA-20-135 – Emergency Competitive Revision to Existing NIH Awards Activity Code/Award: UM1/A1068614-15 (parent award) ------------------------------------------------------------------------------------ Project Abstract This proposal outlines the scientific agenda for the CO…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Peter B. Gilbert · FRED HUTCHINSON CANCER CENTER · 2022 · $260,795 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine efficacy trial entitled “A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficac…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Thomas Parks Remcho · TULANE UNIVERSITY OF LOUISIANA · 2024 · $53,167 — Pneumonia is the leading killer of children globally and a significant cause of morbidity and mortality in the US. Pneumonias due to drug-resistant Enterobacteriaceae are an emerging problem. Our lab has shown that lung tissue resident memory (TRM) cells, consisting of Th17 and Th1 cells, provide pr…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $240,000 — Rift Valley fever virus (RVFV), a bunyavirus, is transmitted by mosquitoes and has caused large outbreaks among humans and ruminants in many countries in Africa and the Arabian Peninsula. RVFV outbreaks in the U.S. are quite possible and would cause serious public health, agricultural, and economic …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Kristina M. Adams Waldorf · UNIVERSITY OF WASHINGTON · 2024 · $843,733 — Project Summary Pregnant women are highly vulnerable to influenza A virus (IAV) and are at increased risk for maternal death, preterm birth and stillbirth. Universal influenza vaccines (UFV) are thought to be possible if conserved regions of influenza virus are targeted and appropriate immune respon…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Amit Kapoor · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2024 · $614,828 — Abstract Although direct acting antivirals can cure Hepatitis C virus (HCV) infection, a vaccine is necessary to stop new infections, and to prevent re-infections in the cured individuals. Studies in humans and chimpanzees suggest that both T cells and neutralizing antibodies (nAb) can play an impor…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
STEVEN GREGORY REED · HDT BIO CORPORATION · 2024 · $543,301 — PROJECT SUMMARY/ABSTRACT Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obst…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Sujan Shresta · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $721,849 — ABSTRACT The long-term goal of this project is to develop a dengue-Zika vaccine that provides protection against the four serotypes of dengue (DENV1-4) and Zika (ZIKV) viruses with maximal safety and efficacy. To date, flavivirus vaccine development has focused on the induction of neutralizing antib…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Styliani Karanika · JOHNS HOPKINS UNIVERSITY · 2024 · $200,880 — PROJECT SUMMARY Host status plays a major role in tuberculosis (TB) disease outcomes, with many efforts to develop host-directed therapies to boost immune response. It is unknown how these strategies will perform in people living with HIV/AIDS (PLWHA) who are at increased risk of adverse TB treatmen…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2024 · $653,018 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
SAMUEL SINGER · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $2,375,406 — ABSTRACT The long-term goal of the SPORE in Soft Tissue Sarcoma is to reduce the morbidity and mortality from soft tissue sarcoma by developing therapies targeted to specific molecular, genetic, epigenetic, and signaling pathway alterations or specific sarcoma type and subtype. To pursue this, we wi…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
SANDHYA VASAN · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2024 · $880,838 — Project Summary/Abstract An HIV-1 (HIV) vaccine capable of eliciting broad and potent neutralizing antibody (Ab) response to HIV envelope (Env) remains elusive. HIV has a high mutation rate, Env is highly glycosylated as well as conformationally dynamic and, well-characterized broadly neutralizing r…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
MING LUO · GEORGIA STATE UNIVERSITY · 2024 · $540,203 — The devastating impact on public health, global economy and social stability incurred by the COVID-19 pandemic in the last two years has highlighted the importance of basic research into zoonotic pathogens. This application describes structural and functional studies into the rodent-borne human path…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $513,877 — ABSTRACT Recent clinical success of mRNA vaccines for COVID-19 has sparked enormous interest in mRNA therapy for a wide range of biomedical applications including protein replacement therapy. However, one unique challenge associated with mRNA therapy is dealing with the transient efficacy due to its…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Denise L. Doolan · UNIVERSITY OF QUEENSLAND · 2024 · $476,538 — PA-19-077 DOOLAN: PROJECT SUMMARY Malaria remains a global public health problem with nearly half of the world's population at risk. An effective malaria vaccine would prevent almost half a million deaths and over 200 million clinical cases each year and help eradicate the disease. The most effectiv…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Yizhou Dong · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $751,497 — PROJECT SUMMARY A vaccine is a promising approach for stopping the spread of HIV infections. Although vaccine regimens in clinical trials show various levels of protection against HIV, there is no effective vaccine available for a large population yet. Preclinical and clinical data demonstrate the i…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Fredrick Heath Damron · WEST VIRGINIA UNIVERSITY · 2024 · $812,208 — PROJECT SUMMARY Pertussis is a respiratory disease caused by the obligate human pathogen Bordetella pertussis. Two generations of pertussis vaccines have been developed and licensed: whole cell pertussis (DTP) and acellular pertussis (DTaP/Tdap). Pertussis was thought to be a disease of the past but…